Top

International Journal of Clinical Oncology

Published in:

01-04-2016 | Original Article

Effect of androgen deprivation therapy on arterial stiffness and serum lipid profile changes in patients with prostate cancer: a prospective study of initial 6-month follow-up

Authors: Ryo Oka, Takanobu Utsumi, Takumi Endo, Masashi Yano, Shuichi Kamijima, Naoto Kamiya, Kohji Shirai, Hiroyoshi Suzuki

Published in: International Journal of Clinical Oncology | Issue 2/2016

Abstract

Background

To explore arterial stiffness during the administration of androgen deprivation therapy (ADT) in patients with prostate cancer (PCa), a new indicator, the cardio-ankle vascular index (CAVI), and serum lipid profile changes were monitored.

Methods

A prospective study assessed the changes in arterial stiffness using the CAVI and clinical laboratory variables among 58 men with prostate cancer treated with ADT for 6 months. Furthermore, patients who had a high risk of developing arterial stiffness after ADT were investigated.

Results

The whole cohort had no significant increase in arterial stiffness within 6 months after ADT, but 55.2 % of patients had an increased CAVI. Serum levels of total cholesterol, high-density-lipoprotein cholesterol (HDL-C), and low-density-lipoprotein cholesterol (LDL-C) increased significantly at 1 month after the start of ADT and maintained high values thereafter. At baseline, HDL-C was lower and LDL-C and LDL-C/HDL-C were higher in the group with than without an increased CAVI after 6 months of ADT administration.

Conclusions

Although the whole cohort did not show a significant change in arterial stiffness with ADT, some patients showed an increased arterial stiffness monitored with the CAVI. The balance between LDL-C and HDL-C, or LDL-C/HDL-C, might have an impact on the development of arterial stiffness after ADT administration. Thus, clinicians might be able to monitor PCa patients who have a high risk of development of arterial stiffness after ADT administration by referring to LDL-C/HDL-C levels.

Suzuki H, Kamiya N, Imamoto T et al (2008) Current topics and perspectives relating to hormone therapy for prostate cancer. Int J Clin Oncol 13:401–410CrossRefPubMed

Kamiya N, Suzuki H, Nishimura K et al (2014) Development of nomogram to non-steroidal antiandrogen sequential alternation in prostate cancer for predictive model. Jpn J Clin Oncol 44:263–269CrossRefPubMed

Imamoto T, Suzuki H, Utsumi T et al (2009) Association between serum sex hormone levels and prostate cancer: effect of prostate cancer on serum testosterone levels. Future Oncol 5:1005–1013CrossRefPubMed

Kamiya N, Suzuki H, Ueda T et al (2014) Clinical outcomes by relative docetaxel dose and dose intensity as chemotherapy for Japanese patients with castration-resistant prostate cancer: a retrospective multi-institutional collaborative study. Int J Clin Oncol 19:157–164CrossRefPubMed

Shahinian VB, Kuo YF, Freeman JL et al (2005) Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer 103:1615–1624CrossRefPubMed

Allan CA, Collins VR, Frydenberg M et al (2014) Androgen deprivation therapy complicaions. Endocr Relat Cancer 21:T119–T129CrossRefPubMed

Smith MR, Finkelstein JS, McGovern FJ et al (2002) Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 87:599–603CrossRefPubMed

Shirai K, Hiruta N, Song M et al (2011) Cardio-ankle vascular index (CAVI) as a novel indicator of arterial stiffness: theory, evidence and perspectives. J Atheroscler Thromb 18:924–938CrossRefPubMed

Nagayama D, Ohira M, Saiki A et al (2014) Sarpogrelate hydrochloride decreases cardio-ankle vascular index accompanied by increased serum lipidprotein lipase mass in type 2 diabetic patients. Int Heart J 55:337–341CrossRefPubMed

10.

Shirai K, Song M, Suzuki J et al (2011) Contradictory effects of β1- and α1-adrenergic receptor blockers on cardio-ankle vascular stiffness index (CAVI)—The independency of CAVI from blood pressure. J Atheroscler Thromb 18:49–55CrossRefPubMed

11.

Dobsak P, Soska V, Sochor O et al (2015) Increased cardio-ankle vascular index in hyperlipidemic patients without diabetes or hypertension. J Atheroscler Thromb 22:272–283CrossRefPubMed

12.

Mizuno K, Nakaya N, Teramoto T et al (2012) Usefulness of LDL-C-related parameters to predict cardiovascular risk and effect of pravastatin in mild-to-moderate hypercholesterolemia. J Atheroscler Thromb 19:176–185CrossRefPubMed

13.

Hasegawa M, Rodbard S (1979) Effect of posture on arterial pressure, timing of the arterial sounds and pulse wave velocities in the extremities. Cardiology 64:122–132CrossRefPubMed

14.

Yamabe T, Yoshizawa M, Saijo Y et al (2004) Brachio-ankle pulse wave velocity and cardio-ankle vascular index (CAVI). Biomed Pharmacother 58(Suppl 1):S95–S98CrossRef

15.

Smith JC, Bennett S, Evans LM et al (2001) The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 86:4261–4267CrossRefPubMed

16.

Dockery F, Bulpitt CJ, Agarwal S et al (2003) Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond) 104:195–201CrossRef

17.

Dockery F, Bulpitt CJ, Agarwal S et al (2009) Effects of androgen suppression compared with androgen receptor blockade on arterial stiffness in men with prostate cancer. J Androl 30:410–415CrossRefPubMed

18.

Deenadayalu VP, White RE, Stallone JN et al (2001) Testosterone relaxes coronary arteries by opening the large-conductance, calcium-activated potassium channel. Am J Physiol Heart Circ Physiol 281:H1720–H1727PubMed

19.

Jones RD, English KM, Pugh PJ et al (2002) Pulmonary vasodilatory action of testosterone: evidence of a calcium antagonistic action. J Cardiovasc Pharmacol 39:814–823CrossRefPubMed

20.

Shahani S, Braga-Basaria M, Basaria S (2008) Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis. J Clin Endocrinol Metab 93:2042–2049CrossRefPubMed

21.

Sağlam, HS, Köse O, Kumsar S et al (2012) Fasting blood glucose and lipid profile alterations following twelve-month androgen deprivation therapy in men with prostate cancer. Sci World J 2012:696329. doi:10.1100/2012/696329

22.

McGrowder DA, Jackson LA, Crawford TV (2012) Prostate cancer and metabolic syndrome: is there a link? Asian Pac J Cancer Prev 13:1–13CrossRefPubMed

23.

Mohamedali HZ, Breunis H, Timilshina N et al (2011) Changes in blood glucose and cholesterol levels due to androgen deprivation therapy in men with non-metastatic prostate cancer. Can Urol Assoc J 5:28–32CrossRefPubMedPubMedCentral

24.

Saylor PJ, Smith MR (2009) Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol 181:1998–2008CrossRefPubMedPubMedCentral

25.

Morote J, Gŏmez-Caamaňo A, Alvarez-Ossorio JL et al (2015) The metabolic syndrome and its components in patients with prostate cancer on androgen deprivation therapy. J Urol 193:1963–1969CrossRefPubMed

26.

Braga-Basaria M, Muller DC, Carducci MA et al (2006) Lipoprotein profile in men with prostate cancer undergoing androgen deprivation therapy. Int J Impot Res 18:494–498CrossRefPubMed

27.

Smith MR, Malkowicz SB, Chu F et al (2008) Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study. J Clin Oncol 26:1824–1829CrossRefPubMedPubMedCentral

28.

Torimoto K, Samma S, Kagebayashi Y et al (2011) The effects of androgen deprivation therapy on lipid metabolism and body composition in Japanese patients with prostate cancer. Jpn J Clin Oncol 41:577–581CrossRefPubMed

29.

Salvador C, Planas J, Agreda F et al (2013) Analysis of the lipid profile and atherogenic risk during androgen deprivation therapy in prostate cancer patients. Urol Int 90:41–44CrossRefPubMed

Title: Effect of androgen deprivation therapy on arterial stiffness and serum lipid profile changes in patients with prostate cancer: a prospective study of initial 6-month follow-up
Authors: Ryo Oka
Takanobu Utsumi
Takumi Endo
Masashi Yano
Shuichi Kamijima
Naoto Kamiya
Kohji Shirai
Hiroyoshi Suzuki
Publication date: 01-04-2016
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 2/2016
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-015-0891-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2016

Relationship between quality of life instruments and phonatory function in tracheoesophageal speech with voice prosthesis

A population-based study on the associations between chronic periodontitis and the risk of cancer

Chemoradiotherapy for T4 and/or M1 lymph node esophageal cancer: experience since 2000 at a high-volume center in Japan

The processus vaginalis transection method is superior to the simple prophylactic procedure for prevention of inguinal hernia after radical prostatectomy

Accuracy of preoperative diagnosis of lymph node metastasis for thoracic esophageal cancer patients from JCOG9907 trial

Analysis of PALB2 mutations in 155 Japanese patients with breast and/or ovarian cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer